Therapy Areas: Devices
Recombinetics Inc and American Preclinical Services to improve Glioblastoma outcomes through animal models
20 October 2020 -

Gene editing company Recombinetics Inc announced on Monday that it has signed a first of its kind partnership with American Preclinical Services to study and improve the outcomes in patients with Glioblastoma, a devastating disease which results in a cancerous tumour that develops in the brain.

Surrogen, a subsidiary of Recombinetics Inc, reportedly displayed the world's first genetically engineered large animal model of Glioblastoma, which develops in a predictable and reproducible timeframe.

This important scientific advancement was achieved through somatic cell gene editing to engineer the precise genetic changes seen in human tumours. This technology is a unique opportunity to impact the lives of those diagnosed with Glioblastoma and to give families hope.

This new animal model of glioblastoma gives the company the opportunity to better understand this disease and improve patient outcomes by identifying tumour biomarkers, developing new surgical and imaging technologies and creating new therapeutic techniques to treat these tumours, added Dr Adrienne Watson, Recombinetics' VP of Research and Development.

Founded in 2005, American Preclinical Services is an AAALAC and ISO17025 accredited, USDA registered and GLP compliant Contract Research Laboratory specializing in medical device and pharmaceutical testing.



Related Headlines